Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Pasquier, M. Kavallaris, N. André (2010)
Metronomic chemotherapy: new rationale for new directionsNature Reviews Clinical Oncology, 7
L. Loeb (2001)
A mutator phenotype in cancer.Cancer research, 61 8
D. Hanahan, G. Bergers, E. Bergsland (2000)
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.The Journal of clinical investigation, 105 8
Rory Martin, K. Teo (1993)
Optimal Control of Drug Administration in Cancer Chemotherapy
(1988)
Optimal treatment protocols in leukemia—modelling the proliferation cycle
(2003)
Minimizing long-term burden: the logic for metronomic chemotherapy dosing and its angiogenic basis
G. Bocci, K. Nicolaou, R. Kerbel (2002)
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.Cancer research, 62 23
L. Weiss (1970)
Introduction to the mathematical theory of control processes, Vol. I - Linear equations and quadratic criteriaIEEE Transactions on Automatic Control, 15
U. Ledzewicz, H. Schättler (2005)
Drug resistance in cancer chemotherapy as an optimal control problemDiscrete and Continuous Dynamical Systems-series B, 6
(2013)
On the MTD paradigm and optimal control for combination cancer chemotherapy
M. Eisen (1979)
Mathematical Models in Cell Biology and Cancer Chemotherapy
M. Chambers (1965)
The Mathematical Theory of Optimal ProcessesJournal of the Operational Research Society, 16
G.W. Swan (1990)
Role of optimal control in cancer chemotherapyMath. Biosci., 101
A. Świerniak, J. Śmieja (2001)
Cancer chemotherapy optimization under evolving drug resistanceNonlinear Analysis-theory Methods & Applications, 47
L. Norton, R. Simon (1986)
The Norton-Simon hypothesis revisited.Cancer treatment reports, 70 1
A. Świerniak, M. Kimmel, J. Śmieja, K. Puszyński, K. Psiuk-Maksymowicz (1995)
Cell Cycle as an Object of ControlJournal of Biological Systems, 03
A. Swierniak (1988)
Proc. of the 12th IMACS
U. Ledzewicz, H. Schättler (2002)
Optimal Bang-Bang Controls for a Two-Compartment Model in Cancer ChemotherapyJournal of Optimization Theory and Applications, 114
J. Greene, Orit Lavi, M. Gottesman, D. Levy (2014)
The Impact of Cell Density and Mutations in a Model of Multidrug Resistance in Solid TumorsBulletin of Mathematical Biology, 76
J. Goldie (2004)
Drug Resistance in Cancer: A PerspectiveCancer and Metastasis Reviews, 20
B. Kamen, E. Rubin, J. Aisner, E. Glatstein (2000)
High-time chemotherapy or high time for low dose.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 16
A. Bressan, B. Piccoli (2007)
Introduction to the Mathematical Theory of Control
Orit Lavi, J. Greene, D. Levy, M. Gottesman (2013)
The role of cell density and intratumoral heterogeneity in multidrug resistance.Cancer research, 73 24
B. Bonnard, M. Chyba (2003)
Singular Trajectories and Their Role in Control TheoryIEEE Transactions on Automatic Control, 50
N. André, L. Padovani, E. Pasquier (2011)
Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?Future oncology, 7 3
P. Hahnfeldt, Lynn Hlatky (1998)
Cell resensitization during protracted dosing of heterogeneous cell populations.Radiation research, 150 6
G. Klement, P. Bőhlen, R. Kerbel (2000)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.The Journal of clinical investigation, 105 8
E. Yagüe, S. Raguz (2005)
Drug resistance in cancerBritish Journal of Cancer, 93
R. Schimke (1984)
Gene amplification, drug resistance, and cancer.Cancer research, 44 5
L. Norton, R. Simon (1977)
Tumor size, sensitivity to therapy, and design of treatment schedules.Cancer treatment reports, 61 7
A. Friedman (2012)
Cancer as Multifaceted DiseaseMathematical Modelling of Natural Phenomena, 7
H. Schättler, U. Ledzewicz (2012)
Geometric Optimal Control
We consider a mathematical model for cancer chemotherapy with a single agent that distinguishes three levels of sensitivities calling the subpopulations ‘sensitive’, ‘partially sensitive’ and ‘resistant’. We analyze the dynamic properties of the system under what could be considered metronomic (continuous, low-dose, constant) chemotherapy and, more generally, also consider the optimal control problem of minimizing the tumor burden over a prescribed therapy interval. Interestingly, when several levels of chemotherapeutic sensitivities are taken into account in the model, lower time-varying dose rates as they are given by singular controls become a treatment option. This is only the case once a significant residuum of resistant cells has been created in a simpler 2-compartment model that only considers sensitive and resistant cells. For heterogeneous tumor populations, a more modulated approach that varies the dose rates of the drugs may be more beneficial than the classical maximum tolerated dose approach pursued in medical practice.
Acta Applicandae Mathematicae – Springer Journals
Published: Jun 10, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.